Therapeutic Potential of Cannabinoids in CNS Disease
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 17 (3) , 179-202
- https://doi.org/10.2165/00023210-200317030-00004
Abstract
The major psychoactive constituent of Cannabis sativa, Δ9-tetrahydrocannabinol (Δ9-THC), and endogenous cannabinoid ligands, such as anandamide, signal through G-protein-coupled cannabinoid receptors...Keywords
This publication has 204 references indexed in Scilit:
- Unsaturated Long-Chain N-Acyl-vanillyl-amides (N-AVAMs): Vanilloid Receptor Ligands That Inhibit Anandamide-Facilitated Transport and Bind to CB1 Cannabinoid ReceptorsBiochemical and Biophysical Research Communications, 1999
- Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexiaJournal of Pain and Symptom Management, 1997
- Paradoxical action of the cannabinoid WIN 55,212‐2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slicesBritish Journal of Pharmacology, 1997
- Substance Use Disorder and the Early Course of Illness in Schizophrenia and Affective PsychosisSchizophrenia Bulletin, 1997
- Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2Life Sciences, 1995
- Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDSJournal of Pain and Symptom Management, 1995
- Clinical Pharmacokinetics of Non-Opiate Abused DrugsClinical Pharmacokinetics, 1989
- Review of Cannabinoids and their Antiemetic EffectivenessDrugs, 1983
- Evaluation of Intramuscular Levonantradol and Placebo in Acute Postoperative PainThe Journal of Clinical Pharmacology, 1981
- Clinical Trials with Antiemetic Agents in Cancer Patients Receiving ChemotherapyThe Journal of Clinical Pharmacology, 1981